Controversies in using urine samples for Prostate Cancer detection: PSA and PCA3 expression analysis

International Braz J Urol

Volumn 37, Issue 6, 2011, Pages 719-726

  Fontenete, S ^a,b   Silva, J ^a,b,c   Teixeira, A L ^a,b,c   Ribeiro, R ^a,b,c   Bastos, E ^d   Pina, F ^e   Medeiros, R ^a,b,c,f  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c Research Department Portuguese League Against Cancer (NRN)   (Portugal)

^d UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

^e University of Porto   (Portugal)

^f UNIVERSIDADE FERNANDO PESSOA   (Portugal)

Author keywords

Biomarkers; Prostate specific antigen; Prostatic neoplasms; Urine

Indexed keywords

MESSENGER RNA; PROSTATE CANCER ANTIGEN 3, HUMAN; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN;

AGED; ARTICLE; BIOPSY; DIGITAL RECTAL EXAMINATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; PATHOLOGY; PROSTATE TUMOR; URINE;

AGED; ANTIGENS, NEOPLASM; BIOPSY; DIGITAL RECTAL EXAMINATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RNA, MESSENGER;

EID: 84861008474     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/S1677-55382011000600006     Document Type: Article

References (29)

1. Downes MR, Byrne JC, Pennington SR, Dunn MJ, Fitzpatrick JM, Watson RW: Urinary markers for prostate cancer. BJU Int. 2007; 99: 263-8.
2. Morote J, Fernández S, Alaña L, Iglesias C, Planas J, Reventós J, et al.: PTOV1 expression predicts prostate cancer in men with isolated high-grade prostatic intraepithelial neoplasia in needle biopsy. Clin Cancer Res. 2008; 14: 2617-22.
3. Loeb S, Catalona WJ: What to do with an abnormal PSA test. Oncologist. 2008; 13: 299-305.
4. Lin DW: Beyond PSA: utility of novel tumor markers in the setting of elevated PSA. Urol Oncol. 2009; 27: 315-21.
5. Schiffer E: Biomarkers for prostate cancer. World J Urol. 2007; 25: 557-62.
6. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, et al.: DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999; 59: 5975-9.
7. Mattick JS, Makunin IV: Non-coding RNA. Hum Mol Genet. 2006; 15(Spec No 1): R17-29.
8. Fradet Y, Saad F, Aprikian A, Dessureault J, Elhilali M, Trudel C, et al.: uPM3, a new molecular urine test for the detection of prostate cancer. Urology. 2004; 64: 311-5; discussion 315-6.
9. Laxman B, Morris DS, Yu J, Siddiqui J, Cao J, Mehra R, et al.: A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res. 2008; 68: 645-9.
10. Steuber T, Helo P, Lilja H: Circulating biomarkers for prostate cancer. World J Urol. 2007; 25: 111-9.
11. Gibson UE, Heid CA, Williams PM: A novel method for real time quantitative RT-PCR. Genome Res. 1996; 6: 995-1001.
12. Jerónimo C, Usadel H, Henrique R, Silva C, Oliveira J, Lopes C, et al.: Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology. 2002; 60: 1131-5.
13. Gonzalgo ML, Isaacs WB: Molecular pathways to prostate cancer. J Urol. 2003; 170: 2444-52.
14. Papatsoris A, Bourdoumis A, Chrisofos MÇ Re: Accuracy of PCA3 Measurement in Predicting Short-Term Biopsy Progression in an Active Surveillance Program J. J. Tosoian, S. Loeb, A. Kettermann, P. Landis, D. J. Elliot, J. I. Epstein, A. W. Partin, H. B. Carter and L. J. Sokoll J Urol 2010; 183: 534-538. J Urol. 2010; 184: 396-7.
15. Hamilton RJ, Goldberg KC, Platz EA, Freedland SJ: The influence of statin medications on prostatespecific antigen levels. J Natl Cancer Inst. 2008; 100: 1511-8.
16. Singer EA, Palapattu GS, van Wijngaarden E: Prostate-specific antigen levels in relation to consumption of nonsteroidal anti-inflammatory drugs and acetaminophen: results from the 2001-2002 National Health and Nutrition Examination Survey. Cancer. 2008; 113: 2053-7.
17. Collins GN, Martin PJ, Wynn-Davies A, Brooman PJ, O'Reilly PH: The effect of digital rectal examination, flexible cystoscopy and prostatic biopsy on free and total prostate specific antigen, and the free-to-total prostate specific antigen ratio in clinical practice. J Urol. 1997; 157: 1744-7.
18. Lin YH, Jiang YG, Li MC, Luo Y, Wang JS: Effects of prostate manipulation on serum total and free prostate specific antigen, and free-to-total prostate specific antigen ratio. Saudi Med J. 2010; 31: 999-1004.
19. Crocitto LE, Korns D, Kretzner L, Shevchuk T, Blair SL, Wilson TG, et al.: Prostate cancer molecular markers GSTP1 and hTERT in expressed prostatic secretions as predictors of biopsy results. Urology. 2004; 64: 821-5.
20. van Gils MP, Hessels D, van Hooij O, Jannink SA, Peelen WP, Hanssen SL, et al.: The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res. 2007; 13: 939-43.
21. Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, et al.: DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol. 2003; 44: 8-15; discussion 15-6.
22. Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C, et al.: APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem. 2006; 52: 1089-95.
23. Marks LS, Fradet Y, Deras IL, Blase A, Mathis J, Aubin SM, et al.: PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology. 2007; 69: 532-5.
24. Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW, et al.: PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol. 2008; 179: 1587-92.
25. Hessels D, Schalken JA: The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol. 2009; 6: 255-61.
26. Thomas CE, Sexton W, Benson K, Sutphen R, Koomen J: Urine collection and processing for protein biomarker discovery and quantification. Cancer Epidemiol Biomarkers Prev. 2010; 19: 953-9.
27. Medeiros M, Sharma VK, Ding R, Yamaji K, Li B, Muthukumar T, et al.: Optimization of RNA yield, purity and mRNA copy number by treatment of urine cell pellets with RNAlater. J Immunol Methods. 2003; 279: 135-42.
28. Tichopad A, Didier A, Pfaffl MW: Inhibition of real-time RT-PCR quantification due to tissue-specific contaminants. Mol Cell Probes. 2004; 18: 45-50.
29. Liss B: Improved quantitative real-time RT-PCR for expression profiling of individual cells. Nucleic Acids Res. 2002; 30: e89.